A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCC

⟵ Back to Search Results

Beigene Study ID

AdvanTIG-206

ClinicalTrials.gov ID

NCT04948697

Sex: All

Age: 18 Years and older (Adult, Older Adult)

No Study Documents

Locations

Sex: All

Age: 18 Years and older (Adult, Older Adult)

No Study Documents